Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Genscript Biotech ( (HK:1548) ).
Genscript Biotech has disclosed that its associate Legend Biotech reported approximately US$555 million in net trade sales of the multiple myeloma cell therapy CARVYKTI® for the quarter ended 31 December 2025, based on figures provided by commercialization partner Janssen Biotech. The announcement underscores the strong commercial traction of CARVYKTI®, which is strategically important to Legend and, by extension, to Genscript’s value proposition, while the company also reminds investors of the inherent risks and uncertainties around pharmaceutical product development, regulatory processes, partnership execution, and competitive dynamics, and advises shareholders to exercise caution when dealing in its securities.
The most recent analyst rating on (HK:1548) stock is a Sell with a HK$13.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
More about Genscript Biotech
Genscript Biotech Corporation, incorporated in the Cayman Islands and listed in Hong Kong, operates in the biotechnology sector and holds an associate stake in Legend Biotech Corporation, which is listed on the Nasdaq in the United States. Through this relationship, Genscript participates indirectly in the development and commercialization of innovative cell therapies such as CARVYKTI®, under a collaboration and license agreement between Legend Biotech and Janssen Biotech.
Average Trading Volume: 9,625,699
Technical Sentiment Signal: Sell
Current Market Cap: HK$30.1B
For an in-depth examination of 1548 stock, go to TipRanks’ Overview page.